SI20072A - Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze - Google Patents

Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze Download PDF

Info

Publication number: SI20072A
Authority: SI; Slovenia
Prior art keywords: hmg; coa reductase; reductase inhibitor; process described; phase
Prior art date: 1998-09-18

Application number

SI9800241A

Other languages

English (en)

Slovenian (sl)

Inventor

Rok Grahek

Du�an Milivojevi�

Andrej Bastarda

Original Assignee

LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-18

Filing date

1998-09-18

Publication date

2000-04-30

1998-09-18 Application filed by LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. filed Critical LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.

1998-09-18 Priority to SI9800241A priority Critical patent/SI20072A/sl

1999-09-17 Priority to AT99941797T priority patent/ATE284396T1/de

1999-09-17 Priority to AU55284/99A priority patent/AU766630B2/en

1999-09-17 Priority to JP2000574092A priority patent/JP3795755B2/ja

1999-09-17 Priority to CA002343645A priority patent/CA2343645A1/en

1999-09-17 Priority to KR1020017000044A priority patent/KR100607608B1/ko

1999-09-17 Priority to CNB998110760A priority patent/CN1186335C/zh

1999-09-17 Priority to ROA200100289A priority patent/RO121116B1/ro

1999-09-17 Priority to US09/720,952 priority patent/US6695969B1/en

1999-09-17 Priority to EP99941797A priority patent/EP1114040B1/en

1999-09-17 Priority to PL345883A priority patent/PL200336B1/pl

1999-09-17 Priority to PCT/IB1999/001553 priority patent/WO2000017182A1/en

1999-09-17 Priority to IL14205699A priority patent/IL142056A0/xx

1999-09-17 Priority to RU2001108381/04A priority patent/RU2235098C2/ru

1999-09-17 Priority to DE69922519T priority patent/DE69922519T2/de

1999-09-17 Priority to HR20010045A priority patent/HRP20010045B1/xx

1999-09-17 Priority to YUP-818/00A priority patent/RS49996B/sr

1999-09-17 Priority to NZ509582A priority patent/NZ509582A/en

1999-09-17 Priority to SK2002-2000A priority patent/SK285868B6/sk

1999-09-17 Priority to SI9930754T priority patent/SI1114040T1/xx

1999-09-17 Priority to HU0102997A priority patent/HUP0102997A2/hu

2000-04-30 Publication of SI20072A publication Critical patent/SI20072A/sl

2001-03-12 Priority to IS5886A priority patent/IS2149B/is

2001-03-16 Priority to BG105348A priority patent/BG64676B1/bg

2001-03-18 Priority to IL142056A priority patent/IL142056A/en

2003-10-30 Priority to US10/698,009 priority patent/US7141602B2/en

2006-10-16 Priority to US11/581,637 priority patent/US20070032549A1/en

Links

238000000034 method Methods 0.000 title claims abstract description 45
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 title abstract 4
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 title abstract 4
239000003112 inhibitor Substances 0.000 title abstract 4
238000002360 preparation method Methods 0.000 title description 2
238000002086 displacement chromatography Methods 0.000 claims abstract description 12
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims abstract description 11
229960002965 pravastatin Drugs 0.000 claims abstract description 11
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims abstract description 11
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims abstract description 6
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims abstract description 6
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims abstract description 6
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims abstract description 6
229960005370 atorvastatin Drugs 0.000 claims abstract description 6
229960004844 lovastatin Drugs 0.000 claims abstract description 6
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims abstract description 6
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims abstract description 6
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims abstract description 6
229960002855 simvastatin Drugs 0.000 claims abstract description 6
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims abstract description 6
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims abstract description 5
229950009116 mevastatin Drugs 0.000 claims abstract description 5
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims abstract description 5
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 31
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 31
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
238000004128 high performance liquid chromatography Methods 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims description 14
230000005526 G1 to G0 transition Effects 0.000 claims description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
238000006073 displacement reaction Methods 0.000 claims description 9
239000000243 solution Substances 0.000 claims description 9
238000000746 purification Methods 0.000 claims description 8
239000000126 substance Substances 0.000 claims description 8
239000002245 particle Substances 0.000 claims description 7
238000004587 chromatography analysis Methods 0.000 claims description 6
150000001298 alcohols Chemical class 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 5
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
-1 alkali metal cations Chemical class 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
238000004458 analytical method Methods 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
229910052783 alkali metal Inorganic materials 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
229910021529 ammonia Inorganic materials 0.000 claims description 2
239000000872 buffer Substances 0.000 claims description 2
230000003750 conditioning effect Effects 0.000 claims description 2
229920006037 cross link polymer Polymers 0.000 claims description 2
238000011010 flushing procedure Methods 0.000 claims description 2
150000007522 mineralic acids Chemical class 0.000 claims description 2
238000011176 pooling Methods 0.000 claims description 2
230000008929 regeneration Effects 0.000 claims description 2
238000011069 regeneration method Methods 0.000 claims description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
239000000741 silica gel Substances 0.000 claims 1
229910002027 silica gel Inorganic materials 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 10
238000002955 isolation Methods 0.000 abstract description 6
239000003814 drug Substances 0.000 abstract description 5
238000000855 fermentation Methods 0.000 abstract description 4
230000004151 fermentation Effects 0.000 abstract description 4
238000003786 synthesis reaction Methods 0.000 abstract description 4
239000013543 active substance Substances 0.000 abstract description 3
230000000326 anti-hypercholesterolaemic effect Effects 0.000 abstract description 3
239000012535 impurity Substances 0.000 abstract description 3
241000187643 Amycolatopsis Species 0.000 abstract description 2
241000228212 Aspergillus Species 0.000 abstract description 2
241000228347 Monascus <ascomycete fungus> Species 0.000 abstract description 2
241000235395 Mucor Species 0.000 abstract description 2
241000187654 Nocardia Species 0.000 abstract description 2
241000228143 Penicillium Species 0.000 abstract description 2
238000009825 accumulation Methods 0.000 abstract description 2
239000008280 blood Substances 0.000 abstract description 2
210000004369 blood Anatomy 0.000 abstract description 2
230000000694 effects Effects 0.000 abstract description 2
230000002349 favourable effect Effects 0.000 abstract description 2
244000005700 microbiome Species 0.000 abstract description 2
230000002265 prevention Effects 0.000 abstract description 2
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
230000035876 healing Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000047 product Substances 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
238000002835 absorbance Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 3
108010040201 Polymyxins Proteins 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000005457 optimization Methods 0.000 description 2
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
HOKIDJSKDBPKTQ-GLXFQSAKSA-N Cephalosporin C Natural products S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 1
241000790917 Dioxys <bee> Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
108010084754 Tuftsin Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
HOKIDJSKDBPKTQ-GLXFQSAKSA-M cephalosporin C(1-) Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H]([NH3+])C([O-])=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-M 0.000 description 1
MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000007273 lactonization reaction Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229940041153 polymyxins Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000003380 propellant Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
241000894007 species Species 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
229940035670 tuftsin Drugs 0.000 description 1
239000010887 waste solvent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/422—Displacement mode
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Crystallography & Structural Chemistry (AREA)
Analytical Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Treatment Of Liquids With Adsorbents In General (AREA)
Pyrrole Compounds (AREA)
Indole Compounds (AREA)
Medicines Containing Plant Substances (AREA)

SI9800241A 1998-09-18 1998-09-18 Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze SI20072A (sl)

Priority Applications (26)

Application Number	Priority Date	Filing Date	Title
SI9800241A SI20072A (sl)	1998-09-18	1998-09-18	Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
HU0102997A HUP0102997A2 (hu)	1998-09-18	1999-09-17	Eljárás nagy tisztaságú HMG-CoA-reduktáz inhibitorok előállítására
RU2001108381/04A RU2235098C2 (ru)	1998-09-18	1999-09-17	Способ получения ингибиторов hmg-coa-редуктазы с высокой степенью чистоты
JP2000574092A JP3795755B2 (ja)	1998-09-18	1999-09-17	高純度のＨＭＧ−ＣｏＡレダクターゼインヒビターを得るためのプロセス
CA002343645A CA2343645A1 (en)	1998-09-18	1999-09-17	Process for obtaining hmg-coa reductase inhibitors of high purity
KR1020017000044A KR100607608B1 (ko)	1998-09-18	1999-09-17	고순도의 ＨＭＧ-ＣｏＡ 환원효소 억제제 생산방법
CNB998110760A CN1186335C (zh)	1998-09-18	1999-09-17	得到高纯度HMG－CoA还原酶抑制剂的方法
ROA200100289A RO121116B1 (ro)	1998-09-18	1999-09-17	Procedeu pentru obţinerea inhibitorilor reductazei hmg-coa
US09/720,952 US6695969B1 (en)	1998-09-18	1999-09-17	Process for obtaining HMG-CoA reductase inhibitors of high purity
EP99941797A EP1114040B1 (en)	1998-09-18	1999-09-17	PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY
PL345883A PL200336B1 (pl)	1998-09-18	1999-09-17	Sposób otrzymywania inhibitorów reduktazy HMG-CoA
PCT/IB1999/001553 WO2000017182A1 (en)	1998-09-18	1999-09-17	PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY
IL14205699A IL142056A0 (en)	1998-09-18	1999-09-17	Process for obtaining hmg-coa reductase inhibitors of high purity
AT99941797T ATE284396T1 (de)	1998-09-18	1999-09-17	Verfahren zur bereitstellung von hochreinen hmg- coa reductase hemmer
DE69922519T DE69922519T2 (de)	1998-09-18	1999-09-17	Verfahren zur bereitstellung von hochreinen hmg-coa reductase hemmer
SI9930754T SI1114040T1 (sh)	1998-09-18	1999-09-17
YUP-818/00A RS49996B (sr)	1998-09-18	1999-09-17	POSTUPAK ZA DOBIJANJE INHIBITORA HMG-CoA REDUKTAZE VISOKE ČISTOĆE
NZ509582A NZ509582A (en)	1998-09-18	1999-09-17	Process for obtaining HMG-CoA reductase inhibitors of high purity using displacement chromatography
SK2002-2000A SK285868B6 (sk)	1998-09-18	1999-09-17	Spôsob získania vysokočistých inhibítorov HMG-CoAreduktázy
HR20010045A HRP20010045B1 (en)	1998-09-18	1999-09-17	PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY
AU55284/99A AU766630B2 (en)	1998-09-18	1999-09-17	Process for obtaining HMG-CoA reductase inhibitors of high purity
IS5886A IS2149B (is)	1998-09-18	2001-03-12	Aðferð til að öðlast mjög hreina HMG-CoA redúktasatálma
BG105348A BG64676B1 (bg)	1998-09-18	2001-03-16	МЕТОД ЗА ПОЛУЧАВАНЕ НА HMG-CoA РЕДУКТАЗНИ ИНХИБИТОРИ С ВИСОКА ЧИСТОТА
IL142056A IL142056A (en)	1998-09-18	2001-03-18	Process for obtaining high-purity HMG – CoA reductase inhibitors
US10/698,009 US7141602B2 (en)	1998-09-18	2003-10-30	Process for obtaining HMG-CoA reductase inhibitors of high purity
US11/581,637 US20070032549A1 (en)	1998-09-18	2006-10-16	Process for obtaining HMG-CoA reductase inhibitors of high purity

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SI9800241A SI20072A (sl)	1998-09-18	1998-09-18	Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze

Publications (1)

Publication Number	Publication Date
SI20072A true SI20072A (sl)	2000-04-30

Family

ID=20432332

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9800241A SI20072A (sl)	1998-09-18	1998-09-18	Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze

Country Status (22)

Country	Link
US (1)	US6695969B1 (sh)
EP (1)	EP1114040B1 (sh)
JP (1)	JP3795755B2 (sh)
KR (1)	KR100607608B1 (sh)
CN (1)	CN1186335C (sh)
AT (1)	ATE284396T1 (sh)
AU (1)	AU766630B2 (sh)
BG (1)	BG64676B1 (sh)
CA (1)	CA2343645A1 (sh)
DE (1)	DE69922519T2 (sh)
HR (1)	HRP20010045B1 (sh)
HU (1)	HUP0102997A2 (sh)
IL (2)	IL142056A0 (sh)
IS (1)	IS2149B (sh)
NZ (1)	NZ509582A (sh)
PL (1)	PL200336B1 (sh)
RO (1)	RO121116B1 (sh)
RS (1)	RS49996B (sh)
RU (1)	RU2235098C2 (sh)
SI (1)	SI20072A (sh)
SK (1)	SK285868B6 (sh)
WO (1)	WO2000017182A1 (sh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7141602B2 (en) *	1998-09-18	2006-11-28	Lek Pharmaceuticals D.D.	Process for obtaining HMG-CoA reductase inhibitors of high purity
SI20305A (sl) *	1999-08-06	2001-02-28	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Kristali natrijeve soli pravastatina
HUP9902352A1 (hu) *	1999-07-12	2000-09-28	Gyógyszerkutató Intézet Kft.	Eljárás pravasztatin mikrobiológiai előállítására
JP3881240B2 (ja) *	1999-11-30	2007-02-14	テバジョジセルジャールザ−トケルエンムケドレ−スベニュタ−ルシャシャ−グ	醗酵ブロスからスタチン化合物を回収するための方法
IL150187A0 (en) *	1999-12-14	2002-12-01	Biogal Pharmaceutical Co Ltd	Novel forms of pravastatin sodium
AU4183301A (en)	2000-03-03	2001-09-17	Biogal Gyogyszergyar	A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
US20050215636A1 (en) *	2000-10-05	2005-09-29	Vilmos Keri	Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
IL155194A0 (en) *	2000-10-05	2003-11-23	Biogal Pharmaceutical Co Ltd	Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US6936731B2 (en)	2000-10-05	2005-08-30	TEVA Gyógyszergyár Részvénytársaság	Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja)	2000-10-16	2001-12-10	三共株式会社	プラバスタチンを精製する方法
JP3463875B2 (ja)	2001-08-06	2003-11-05	三共株式会社	プラバスタチンを精製する方法
KR100407758B1 (ko) *	2001-08-27	2003-12-01	씨제이 주식회사	스타틴의 제조에 있어서 락톤화 방법
JP2003093045A (ja) *	2001-09-26	2003-04-02	Godo Shusei Co Ltd	有用変換微生物
KR100435078B1 (ko) *	2002-02-08	2004-06-09	종근당바이오 주식회사	심바스타틴의 정제방법
JP3463881B2 (ja)	2002-08-06	2003-11-05	三共株式会社	プラバスタチン又はその薬理上許容される塩の単離・精製方法
EP1613760A2 (en) *	2003-04-01	2006-01-11	Ranbaxy Laboratories, Ltd.	Fermentation process for the preparation of pravastatin
US6978908B2 (en) *	2003-09-15	2005-12-27	Gerber Products Company	Drinking vessel with adjustable handles
DE202004020671U1 (de) *	2003-11-24	2005-12-08	Teva Gyogyszergyar Reszvenytarsasag	Pravastatin
ES2239533B1 (es) *	2004-03-01	2006-12-16	Ercros Industrial, S.A.	Procedimiento para la obtencion de compactina.
ES2263407T1 (es) *	2004-09-28	2006-12-16	Teva Pharmaceutical Industries Ltd	Procedimiento para la preparacion de formas de atorvastatina calcica sustancialmente libres de impurezas.
CN102043030A (zh) *	2009-10-22	2011-05-04	北京万全阳光医学技术有限公司	一种用高效液相色谱法测定烟酸辛伐他汀缓释片有关物质的方法
CN102621238A (zh) *	2011-02-01	2012-08-01	北京北大维信生物科技有限公司	一种测定HMG-CoA还原酶抑制剂浓度的方法
CN105985244A (zh) *	2015-02-04	2016-10-05	北京北大维信生物科技有限公司	化合物、其分离方法、合成方法及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4231938A (en) *	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
SU1319352A1 (ru) *	1985-01-07	1995-09-10	Ленинградский государственный университет им.А.А.Жданова	Способ очистки препарата гистона н4 из ткани тимуса
IT1232311B (it)	1989-09-04	1992-01-28	Sclavo Spa	Metodo di purificazione di composti a struttura peptidica o pseudo peptidica a basso peso molecolare.
US5202029A (en) *	1991-03-13	1993-04-13	Caron Kabushiki Kaisha	Process for purification of hmg-coa reductase inhibitors
EP0575616A4 (en) *	1991-03-14	1996-07-10	Ace Denken Kk	Stock control system
US5420024A (en) *	1993-05-11	1995-05-30	Merck & Co., Inc.	Process for synthesis of acylated HMG-CoA reductase inhibitors from a lactone diol precursor using Candida cylindracea
US5427686A (en) *	1994-04-05	1995-06-27	Sri International	Process for separating material from mixture using displacement chromatography
EP0877089A1 (en) *	1997-05-07	1998-11-11	Gist-Brocades B.V.	HMG-CoA reductase inhibitor preparation process

1998
- 1998-09-18 SI SI9800241A patent/SI20072A/sl not_active IP Right Cessation
1999
- 1999-09-17 DE DE69922519T patent/DE69922519T2/de not_active Expired - Lifetime
- 1999-09-17 HR HR20010045A patent/HRP20010045B1/xx not_active IP Right Cessation
- 1999-09-17 RO ROA200100289A patent/RO121116B1/ro unknown
- 1999-09-17 HU HU0102997A patent/HUP0102997A2/hu unknown
- 1999-09-17 CA CA002343645A patent/CA2343645A1/en not_active Abandoned
- 1999-09-17 SK SK2002-2000A patent/SK285868B6/sk not_active IP Right Cessation
- 1999-09-17 RS YUP-818/00A patent/RS49996B/sr unknown
- 1999-09-17 US US09/720,952 patent/US6695969B1/en not_active Expired - Fee Related
- 1999-09-17 PL PL345883A patent/PL200336B1/pl not_active IP Right Cessation
- 1999-09-17 IL IL14205699A patent/IL142056A0/xx active IP Right Grant
- 1999-09-17 KR KR1020017000044A patent/KR100607608B1/ko not_active Expired - Fee Related
- 1999-09-17 RU RU2001108381/04A patent/RU2235098C2/ru not_active IP Right Cessation
- 1999-09-17 NZ NZ509582A patent/NZ509582A/en not_active IP Right Cessation
- 1999-09-17 CN CNB998110760A patent/CN1186335C/zh not_active Expired - Fee Related
- 1999-09-17 AT AT99941797T patent/ATE284396T1/de active
- 1999-09-17 EP EP99941797A patent/EP1114040B1/en not_active Expired - Lifetime
- 1999-09-17 AU AU55284/99A patent/AU766630B2/en not_active Ceased
- 1999-09-17 JP JP2000574092A patent/JP3795755B2/ja not_active Expired - Fee Related
- 1999-09-17 WO PCT/IB1999/001553 patent/WO2000017182A1/en not_active Ceased
2001
- 2001-03-12 IS IS5886A patent/IS2149B/is unknown
- 2001-03-16 BG BG105348A patent/BG64676B1/bg unknown
- 2001-03-18 IL IL142056A patent/IL142056A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU766630B2 (en)	2003-10-23
NZ509582A (en)	2003-10-31
CN1186335C (zh)	2005-01-26
PL345883A1 (en)	2002-01-14
IL142056A (en)	2006-08-01
CA2343645A1 (en)	2000-03-30
JP2002526486A (ja)	2002-08-20
DE69922519T2 (de)	2005-12-08
RO121116B1 (ro)	2006-12-29
HRP20010045A2 (en)	2001-12-31
RS49996B (sr)	2008-09-29
HUP0102997A2 (hu)	2001-12-28
SK20022000A3 (sk)	2001-08-06
CN1318063A (zh)	2001-10-17
KR100607608B1 (ko)	2006-08-02
JP3795755B2 (ja)	2006-07-12
EP1114040A1 (en)	2001-07-11
IS2149B (is)	2006-10-13
US6695969B1 (en)	2004-02-24
WO2000017182A1 (en)	2000-03-30
KR20010099584A (ko)	2001-11-09
HRP20010045B1 (en)	2005-08-31
IL142056A0 (en)	2002-03-10
PL200336B1 (pl)	2008-12-31
SK285868B6 (sk)	2007-10-04
ATE284396T1 (de)	2004-12-15
BG105348A (en)	2001-11-30
RU2235098C2 (ru)	2004-08-27
AU5528499A (en)	2000-04-10
DE69922519D1 (de)	2005-01-13
BG64676B1 (bg)	2005-11-30
IS5886A (is)	2001-03-12
YU81800A (sh)	2003-02-28
EP1114040B1 (en)	2004-12-08

Publication	Publication Date	Title
SI20072A (sl)	2000-04-30	Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
KR960002868B1 (ko)	1996-02-27	글리코펩티드 항생물질의 회수 방법
US7141602B2 (en)	2006-11-28	Process for obtaining HMG-CoA reductase inhibitors of high purity
Feibush et al.	1991	Hydrophilic shielding of hydrophobic, cation-and anion-exchange phases for separation of small analytes: direct injection of biological fluids onto high-performance liquid chromatographic columns
CN1134449C (zh)	2004-01-14	制备默诺霉素a的方法
CN116381068A (zh)	2023-07-04	一种分离并检测玛巴洛沙韦中有关物质的高效液相色谱法
CA3095340A1 (en)	2019-10-03	Novel saponin adjuvant and evaluation method thereof
US5854390A (en)	1998-12-29	Chromatographic purification of vancomycin hydrochloride by use of preparative HPLC
US8435938B2 (en)	2013-05-07	Pure vancomycin hydrochloride
CZ2001137A3 (cs)	2001-05-16	Způsob získání inhibitorů HMG-CoA reduktázy vysoké čistoty
CN112279895A (zh)	2021-01-29	一种化学合成酸性多肽的制备方法
US6767998B2 (en)	2004-07-27	Method for preparing purified erythromycin
Tomori et al.	1984	High-performance liquid chromatography of a new tripeptide aldehyde (GYKI-14 166), correlation between the structure and activity
Shenbagamurthi et al.	1983	Purification of synthetic analogues of yeast mating hormone by reversed-phase chromatography

Legal Events

Date	Code	Title	Description
2005-01-10	IF	Valid on the event date
2008-12-31	KO00	Lapse of patent	Effective date: 20081015